Discovery of Potent and Selective VHL-Recruiting PROTAC Degraders Targeting EGFR with Improved Developability and Potent Anti-NSCLC Efficacy
D4 was orally bioavailable and blood−brain barrier penetrant and completely inhibited tumor growth in vivo after oral dosing and provides promising starting points for next-generation EGFR-directed therapy.